Previous 10 | Next 10 |
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024. The Company will hold a conference call at 4:30 p....
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
A look at the top 10 most actives in the United States Beamr Imaging Ltd. (BMR) rose 687.2% to $16.61 on volume of 140,756,692 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 0.0% to $4.3084 on volume of 120,282,414 shares Arm Holdings plc (ARM) rose 26.0% to $145.1201 on v...
2024-02-12 13:29:17 ET More on Sangamo Therapeutics Seeking Alpha’s Quant Rating on Sangamo Therapeutics Historical earnings data for Sangamo Therapeutics Financial information for Sangamo Therapeutics Read the full article on Seeking Alpha For...
- U.S. Food and Drug Administration (FDA) advises that a single study with up to 25 patients, in combination with confirmatory evidence, may be acceptable pathway to Biologics License Application (BLA) submission for isaralgagene civaparvovec, which would significantly reduce anticipated comple...
- Sustained elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for up to three years for the longest-treated patient as of the data cutoff date. - All 12 patients withdrawn from enzyme replacement therapy (ERT) remain off ERT, with sustained elevated ...
2023-11-21 15:13:40 ET More on Beam, CRISPR, etc. Intellia: Soon-To-Be Enrollment Completion Brings About Catalysts In 2024 Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript) Beam Therapeutics: Sale Of Rights To Verve's In Vivo Ca...
2023-11-06 14:45:28 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q3 2023 Earnings Call Transcript Sangamo Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction ...
2023-11-03 15:32:03 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q3 2023 Earnings Call Transcript Sangamo Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction ...
News, Short Squeeze, Breakout and More Instantly...
Sangamo Therapeutics Inc. Company Name:
SGMO Stock Symbol:
NASDAQ Market:
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. The company will hold a conference call at 4:30 p.m. Eastern on Thurs...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27 th ASGCT Annual Meeting being held May 7-11, 2024, in-person in Baltimore, MD and in...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an aggregate of 24,761,905 shares of its common stock and pre-funded warrants to pur...